吉林长龙药业(08049) - 2022 - 年度财报

The accompanying notes form an integral part of these consolidated financial statements. 隨附之附註屬本綜合財務報表整體之一部分。 MANAGEMENT DISCUSSION AND ANALYSIS 管理層討論及分析 The accompanying notes form an integral part of these consolidated financial statements. 隨附之附註屬本綜合財務報表整體之一部分。 Jilin Province Huinan Changlong Bio-pharmacy Company Limited ANNUAL REPORT 2022 50 As at 31 December 2022, the Company held Wealth Management Products totalling approximately RMB263,074,000. Information of the Wealth Management Products held by the ...